ORIGINAL ARTICLE

Metabolic phenotype-microRNA data fusion analysis of the systemic consequences of Roux-en-Y gastric bypass surgery

Q Wu,1,6 JV Li,1,2,6 F Seyfried,3 CW Le Roux,4,5 H Ashrafian,1 T Athanasiou,1 W Fenske,5 A Darzi,1 JK Nicholson,1,2, E Holmes1,2 and NJ Gooderham1

BACKGROUND/OBJECTIVES: Bariatric surgery offers sustained marked weight loss and often remission of type 2 diabetes, yet the mechanisms of establishment of these health benefits are not clear.

SUBJECTS/METHODS: We mapped the coordinated systemic responses of gut hormones, the circulating miRNAome and the metabolome in a rat model of Roux-en-Y gastric bypass (RYGB) surgery.

RESULTS: The response of circulating microRNAs (miRNAs) to RYGB was striking and selective. Analysis of 14 significantly altered circulating miRNAs within a pathway context was suggestive of modulation of signaling pathways including G protein signaling, neurodegeneration, inflammation, and growth and apoptosis responses. Concomitant alterations in the metabolome indicated increased glucose transport, accelerated glycolysis and inhibited gluconeogenesis in the liver. Of particular significance, we show significantly decreased circulating miRNA-122 levels and a more modest decline in hepatic levels, following surgery. In mechanistic studies, manipulation of miRNA-122 levels in a cell model induced changes in the activity of key enzymes involved in hepatic energy metabolism, glucose transport, glycolysis, tricarboxylic acid cycle, pentose phosphate shunt, fatty-acid oxidation and gluconeogenesis, consistent with the findings of the in vivo surgery-mediated responses, indicating the powerful homeostatic activity of the miRNAs.

CONCLUSIONS: The close association between energy metabolism, neuronal signaling and gut microbial metabolites derived from the circulating miRNA, plasma, urine and liver metabolite and gut hormone correlations further supports an enhanced gut-brain signaling, which we suggest is hormonally mediated by both traditional gut hormones and miRNAs. This transomic approach to map the crosstalk between the circulating miRNAome and metabolome offers opportunities to understand complex systems biology within a disease and interventional treatment setting.

International Journal of Obesity (2015) 39, 1126–1134; doi:10.1038/ijo.2015.33

INTRODUCTION

Obesity and its comorbidities have reached epidemic proportions across the developed and developing world, imposing an unsustainable socioeconomic burden on many societies.1 Bariatric surgery is the most effective treatment strategy for morbidly obese patients (body mass index > 40 kg m−2), or those with obesity comorbidities at a lower body mass index, as it can achieve sustained long-term weight loss and place type 2 diabetes in remission within days.2 Unlike diet-induced weight loss, Roux-en-Y gastric bypass (RYGB) achieves substantial weight loss with enhanced satiety, decreased hunger and increased energy expenditure while food restriction and malabsorption have not been identified as major players, in addition to reduced food intake.3 However, although the anatomical rearrangement leads to enterohormonal changes, altered bile flow4 profound changes of the gut microbiota5,6 and downregulation of endocannabinoids,7 the mechanism by which RYGB modulates metabolic pathways in an integrated way and the molecules responsible for coordinating these effects remain largely unknown.

MicroRNAs (miRNAs) are non-coding RNAs, 18–25 nucleotides in length, which regulate thousands of genes at the post-transcriptional level;8 each miRNA can potentially target multiple mRNAs. This multi-targeting feature of miRNAs defines their unique role in governing multiple metabolic processes simultaneously. With their ability to influence pathway networks and high expression level in cells, miRNAs are believed to confer biological system robustness under homeostatic disturbance.9 We hypothesized that following RYGB surgery, which profoundly changes nutrients and bile flow, the individual establishes a new metabolic balance via the manipulation of miRNAs. Therefore, we profiled and integrated the plasma miRNAome and metabolome from Sprague Dawley (SD) rats undergoing RYGB surgery using a Statistical Heterospectroscopy (SHY) method,10 aiming to probe the composition of circulating miRNAs, which could behave as master metabolic regulators mediating post RYGB biological effects. Subsequent downstream in vitro model was used to probe these miRNA-mediated metabolic pathway alterations post RYGB surgery.

MATERIALS AND METHODS

Experiment design and sample collection
The animal experiment was carried out under a UK home office licence (PL 70-6669). Thirteen male SD rats were individually housed and kept under a...
12 h/12 h light/dark cycle at room temperature. All rats were acclimatized and fed high-fat diet for 1 week prior to the experiment. Animals were randomly divided into two groups: RYGB (n = 8) and SHAM (n = 5). The antibiotic combination amoxicillin/flucloxacinil was administered pre-surgery to all rats at a dose of 12.5 mg per rat.

Animal body weight (BW) and food intake were measured daily. The gut hormones (for example, peptide YY (PYY) and glucagon-like peptide 1 (GLP-1)) were measured on the day of killing. Blood was collected from all groups in the fasting state via cardiac puncture under terminal anesthesia in tubes containing EDTA and dipherpidyl peptide-4 inhibitor. The plasma fraction was separated by centrifugation at 4 °C and stored at –80 °C. All samples were assayed in duplicate. PYY-like immunoactivity was measured with a specific and sensitive radioimmunoassay, which measure both the full length (PYY1-36) and the fragment (PYY3-35). GLP-1 was measured in duplicate by established in-house radioimmunoassay (Millipore, Billerica, MA, USA).

Spot urinary samples were collected at day 52 and all rats were culled 53 days after the surgery. Approximately 5 ml of whole blood was taken from the heart, 2.5 ml of which was transferred into an EDTA-containing tube (BD Bioscience, Oxford, UK) and the remaining to a sodium heparin-coated tube. After a gentle shake, they were immediately centrifuged at 3500 g at room temperature for 10 min. The resulting plasma samples were collected into two 1.5-ml RNase-free Eppendorf tubes, separately. The left lobe of the liver was collected from each rat. All samples were immediately snap-frozen in liquid nitrogen and stored at –80 °C.

Sample preparation for NMR spectroscopic analyses
Plasma samples collected using sodium heparin and urine were thoroughly defrosted and vortexed for 15 s. A total of 30 μl of urine was mixed with 25 μl of 0.2 M sodium phosphate buffer in deuterium oxide (0.01% of sodium 3-trimethylsilyl) propionate-2,2,3,3-d4, pH = 7.4), and 50 μl of the mixture was transferred into a nuclear magnetic resonance (NMR) tube with an outer diameter of 1.7 mm for further spectroscopic analysis. A total of 400 μl of plasma was mixed with 250 μl of saline containing 20% deuterium oxide for the magnetic field lock. The resulting mixture was centrifuged at 10 000 g for 10 min, and 600 μl of supernatant was transferred into a NMR tube with an outer diameter of 5 mm pending 1H NMR spectral acquisition. The liver tissue extraction is described in SI Materials and Methods. The dry extracts of liver aqueous phase were resuspended in a mixture of 100 μl water, 400 μl deuterium oxide and 400 μl aforementioned sodium phosphate buffer, centrifuged for 10 min at 10 000 g, and 600 μl of supernatant was transferred into a NMR tube.

1H Nuclear magnetic resonance spectroscopy of urine, plasma and liver extracts, and spectral data analysis
1H NMR spectra of urine, plasma and liver aqueous extract samples were obtained using a Bruker 600 MHz spectrometer (Bruker; Rheinstetten, Germany) at the operating 1H frequency of 600.13 MHz with a temperature of 300 K. A standard NMR pulse sequence (recycle delay (RD)–90°–t1–90°–t1’–90°–acquisition) was applied to acquire one-dimensional 1H NMR spectral data, where t1 was set to 3 μs and t1’ (mixing time) was set to 100 ms. Suppression of the water peak was achieved using selective irradiation during RD of 2 s and t1. A 90 degree pulse was adjusted to ~10 μs. A total of 128 scans for plasma samples and 256 scans for liver aqueous extracts were collected into 64 k data points with a spectral width of 20 ppm. A Carr–Purcell–Meiboom–Gill pulse sequence (RD–90°–t1–180°–t1’–acquisition) was applied additionally to plasma samples to better visualize the signals of the low molecular weight metabolites. For the Carr–Purcell–Meiboom–Gill experiment, a spin relaxation delay (2nτ) of 64 ms was used.

1H NMR spectral data processing and multivariate statistical analysis are described in Supplementary Information Materials and Methods.

RNA isolation, reverse transcription and preamplification for Taqman miRNA low-density array
Total miRNAs in plasma and the liver homogenates were extracted using a miRNA Isolation kit (Ambion, Paisley, UK). Preparations for the liver RNA extraction followed the manufacturer’s instruction, whereas for plasma samples, minor modifications were applied to better eliminate plasma protein. In brief, 100 μl of the plasma sample was diluted with 100 μl cell disruption buffer and then 200 μl of 2X denature solution was added. The remaining extraction steps are the same as the manufacturer’s instructions. RNAs from both plasma and liver tissues were eluted from miVANA PARIS columns using 100 μl of 95% CDNase and RNase-free water and stored at −20 °C pending analysis.

Total RNA was reverse transcribed using Taqman Megaplex pools. Reverse transcription (RT) mix was prepared following the manufacturer’s instructions. RT mix (4.5 μl) was mixed with 3 μl total RNA extracted from plasma. The RT products were preamplified according to the manufacturer’s recommendations. RT product (2.5 μl) was combined with 12.5 μl Taqman PreAmp Master Mix (2X) and 2.5 μl Megaplex PreAmp Primers (10X) to generate a final 25 μl preamplification PCR mix. Preamplification was carried out following the manufacturer’s instructions. Preamplification PCR product (10 μl) was diluted with 30 μl 0.1X TE buffer (pH 8.0). The diluted preamplification PCR product was stored at −20 °C until required.

Taqman miRNA low-density array
Taqman Array Rodent Card is able to detect all 373 miRNAs expressed in rat according to the Sanger mirBase v15. Each complete assay contain two sets of cards (Card A and B). Card A detects well-characterized miRNAs, which tend to be function defined and broadly/highly expressed. Card B detects most of the recently discovered, less functional defined and narrowly or low-expressed miRNAs. Diluted preamplification product (9 μl) was combined with 450 μl Taqman universal PCR Master Mix (no AmpErase UNG) and 441 μl RNase-free water to generate a final 100 μl PCR reaction mixture. Quantitative PCR reaction mix (100 μl) was loaded into each port of the TaqMan MicroRNA Array. The array card was centrifuged at 331 g for 2 min and then mechanically sealed with Applied Biosystems 7900HT upgrade kit. Quantitative RT-PCR reaction was carried out using an Applied Biosystems 7900HT thermocycler according to the manufacturer’s recommended cycling conditions. The single Taqman miRNA assay, miRNA target prediction, protein extraction from the liver and Immunoblot, miRDIAN miR-122 mimic transfection, and statistical correlation analysis among gut hormones, miRNAome and metabolome are described in SI Materials and Methods.

RESULTS
RYGB surgery alters gut hormone levels and metabolite profiles of urine, plasma and liver extracts in SD rats
RYGB surgery induced a reduction of 22.0% of pre-surgical BW in SD rats (n = 8) over 52 days (pre-surgery BW = 467.9 ± 12.9 g, post-surgery BW = 377.8 ± 33.9 g), whereas sham-operated animals (n = 5) had an average BW of 573.2 g over the experimental period (Supplementary Figure S1A). Consistent with previous studies,17 we observed that the plasma concentrations of gut hormones, GLP-1 and PYY, were significantly elevated following RYGB surgery (GLP-1(sham) = 71.5 ± 11.7 pmol l−1, GLP-1(rygB) = 105.3 ± 3.3 pmol l−1, P < 0.001; PYY(sham) = 262 ± 5.6 pmol l−1, PYY(rygB) = 104.8 ± 48 pmol l−1, P < 0.001) (Supplementary Figures S1B and C).

Orthogonal partial least squares-discriminant analysis (OPLS-DA) of 1H nuclear magnetic resonance (NMR) spectroscopic data of urine, plasma and liver tissue collected 52 days post operation showed clear postoperative shift in metabolism in all matrices (Supplementary Figure S2, Table 1). Similar to our previous findings in Wistar rats and C57BL6 mice, urinary concentrations of citrate, fumarate, 2-oxoglutarate and succinate decreased post RYGB surgery, suggesting an enhancement in tricarboxylic acid cycle (TCA) activity.6,12 Increased urinary excretion of host-microbial co-metabolites including indoxyl sulfate, p-cresyl sulfate, p-cresyl glucuronide, phenylacetylglycine and trimethylamine N-oxide were observed. RYGB reduced plasma lipids and increased pyruvate, lactate and alanine, suggesting increased lipid metabolism and glycolysis. Elevations in the concentrations of hepatic glycogen, glucose, glyceral, lactate and alanine are consistent with the downregulation of gluconeogenesis and an increased conversion between glycogen and glucose. These observations of altered hormonal and metabolic status support extant literature and suggest that RYGB extensively regulates multiple energy metabolism-related pathways.
Table 1. Plasma, urinary and hepatic aqueous metabolites found to be altered between RYGB- and SHAM-operated rats based on OPLS-DA models

### Plasma metabolite

| Metabolite                  | Change in RYGB | Peak (ppm) | P-value | q-value |
|-----------------------------|----------------|------------|---------|---------|
| CH₃                         | ↓              | 0.87       | 0.002   | 0.025   |
| (CH₂)ₙ                       | ↓              | 1.266      | 0.005   | 0.03    |
| CH₃CH₂CO                    | ↓              | 1.562      | 0.006   | 0.03    |
| CH₃C=O                      | ↓              | 2.036      | 0.002   | 0.02    |
| CH₃CH=O                     | ↓              | 2.227      | 0.004   | 0.03    |
| Pyruvate                     | ↑              | 5.3        | 0.007   | 0.03    |
| Lactate                      | ↑              | 2.357      | 0.006   | 0.03    |
| D-3-hydroxybutyrate          | ↑              | 1.178      | 0.09    | 0.14    |
| Glutamine                    | ↓              | 2.426      | 0.003   | 0.03    |
| Glucose                      | ↑              | 0.02       | 0.06    |
| Creatine                     | ↑              | 0.04       | 0.03    |
| TMAO+betain                  | ↓              | 3.252      | 0.004   | 0.03    |
| GLYCO                       | ↓              | 3.566      | <0.001  | 0.01    |
| 2-deoxyctydine               | ↓              | 6.04       | <0.001  | 0.02    |
| Formate                      | ↑              | 8.443      | <0.001  | 0.003   |
| Phenylalanine                | ↓              | 7.407      | 0.004   | 0.03    |
| Acetate                      | ↑              | 1.904      | 0.03    | 0.06    |
| 2-phenylpropionate*          | ↑              | 1.425      | <0.001  | 0.005   |
| Alanine                      | ↑              | 1.471      | <0.001  | 0.005   |
| Lysine                       | ↑              | 1.892      | <0.001  | 0.006   |
| 3-aminoisobutyrate*          | ↑              | 1.2        | 0.004   | 0.03    |

### Urinary metabolite

| Metabolite                  | Change in RYGB | Peak (ppm) | P-value | q-value |
|-----------------------------|----------------|------------|---------|---------|
| Succinate                    | ↓              | 2.413      | <0.001  | <0.001  |
| 2-oxoglutarate               | ↓              | 2.448      | <0.001  | <0.001  |
| Citrate                      | ↑              | 5.528      | <0.001  | <0.001  |
| Fumarate                     | ↓              | 1.824      | <0.001  | <0.001  |
| 5-aminovalerate              | ↑              | 1.645      | 0.05    | 0.06    |
| Pimelate                     | ↑              | 1.31       | 0.004   | 0.01    |
| TMAO                         | ↑              | 3.273      | 0.002   | 0.007   |
| Taurine                      | ↓              | 3.433      | 0.002   | 0.006   |
| Creatine                     | ↑              | 3.933      | 0.1     | 0.09    |
| Creatinine                   | ↓              | 4.054      | <0.001  | 0.003   |
| 4-hydroxyphenylacetate       | ↑              | 3.454      | 0.001   | 0.004   |
| Unknown                      | ↑              | 3.523      | 0.002   | 0.006   |
| p-cresyl glucuronide         | ↑              | 2.301      | 0.002   | 0.005   |
| p-cresyl sulfate             | ↑              | 2.346      | 0.002   | 0.007   |
| PAG                          | ↑              | 3.757      | <0.001  | <0.001  |
| Hipurate                     | ↓              | 3.974      | 0.009   | 0.02    |
| Trigonelline                 | ↓              | 4.436      | <0.001  | <0.001  |
| Indoxyl sulfate              | ↑              | 7.714      | <0.001  | 0.002   |

### Liver metabolite

| Metabolite                  | Change in RYGB | Peak (ppm) | P-value | q-value |
|-----------------------------|----------------|------------|---------|---------|
| Lactate                      | ↑              | 1.339      | 0.001   | 0.005   |
| Alanine                      | ↑              | 1.479      | 0.01    | 0.02    |
| Glucose                      | ↑              | 5.238      | <0.001  | 0.002   |
| Glycogen                     | ↑              | 5.415      | <0.001  | 0.002   |
| Glycerol                     | ↑              | 3.78       | <0.001  | 0.001   |
| Uracil                       | ↑              | 5.803      | 0.03    | 0.05    |
| Hypoxanthine                 | ↑              | 8.2        | 0.006   | 0.02    |

Abbreviations: CPMG, Carr-Purcell-Meiboom-Gill; OPLS-DA, orthogonal-partial least squares-discriminant analysis; PAG, phenylacetylglucose; RYGB, Roux-en-Y gastric bypass; TMAO, trimethylamine-N-oxide. R²X represents the variation in ¹H NMR spectral data explained by the OPLS-DA model. Q²Y indicates the level of significance of the metabolic differences between two classes. The P- and q-values in the table represent the significance of the metabolite changes and false discovery rate-adjusted P-values, respectively. The arrow up or arrow down represents the increased or decreased trend of metabolites in RYGB-operated rats compared with SHAM controls. *Tentative metabolite assignment.
RYGB profoundly influences the global circulating miRNA expression in plasma

We next investigated the influence of RYGB on the circulating miRNAome using Taqman low-density array cards. Normalization is a key issue in circulating miRNA data analysis, thus we first developed a method for normalization of multiple-miRNAs and demonstrated its superiority over the widely used spike-in Caenorhabditis elegans cel-miR-39, global normalization and U6 normalization methods (as detailed in the Supplementary information, Supplementary Figure S3). Raw miRNA data were normalized using five endogenous miRNAs (U6-1, U6-2 mir-16, mir-223 and mir-1937b), and a total of 113 and 92 plasma circulating miRNAs were detected in four RYG- and four SHAM-operated rats, respectively, 88 of which were common to both groups (Supplementary Table S1). Fourteen miRNAs were found to be significantly differentially expressed using a two-tailed student t-test (P < 0.05) (Figure 1a). Eleven of the altered miRNAs were downregulated (miR-122, miR-93*, miR-872, miR-7*, miR-146a, miR-342-3p, miR-150, miR-139, miR-30a, miR-30e, miR-320), whereas three miRNAs, namely miR-463*, miR-34c* and miR-1188, were upregulated in the RYGB group. The clustered miRNA profiles show clear differentiation of the RYGB and SHAM groups (Figure 1b), wherein the RYGB-altered miRNAs typically exhibited a 1.5- to sixfold change compared with sham-operated rats, with the exception of miR-122, which demonstrated a 56-fold (P = 0.0095) downregulation in RYGB-operated animals. This is consistent with a previous finding in RYGB patients, where miR-122 decreased significantly (~94.2%, P < 0.0001) when comparing baseline and after surgery miR-122 levels. Therefore, our data support the hypothesis that RYG significantly alters circulating miRNAs, and thus the metabolic consequences of this require further investigation.

RYGB-altered plasma miRNAs influence multiple inflammation, obesity and neurodegenerative disease-related pathways

To gain insight into miRNA-mediated metabolic pathways affected by RYGB surgery, we predicted the mRNA targets of each of these altered circulating miRNAs with nine commonly used databases (See Materials and Methods) and retained only targets predicted by more than two programmes for further analysis. Based on the predicted pathways ranked according to the number of discriminatory miRNAs involved in each pathway (Figure 1c), we found that signaling pathways, specifically G protein signaling, neurodegenerative, inflammation, and growth and apoptosis were highly likely to be influenced by the surgery. In particular, miR-342-3p, miR-320, miR-139-5p and miR-146a were predicted to be involved in multiple neurological transmitter and receptor-related pathways, as well as two major neurodegenerative disease-associated pathways (Parkinson’s and Huntingtons diseases), suggesting that RYG surgery may modulate neurological activity through a miRNA-mediated gut-brain axis. Nine out of these 14 RYG-altered miRNAs are associated with Parkinson’s disease.

Correlation between miRNAome and the metabolic phenotype post RYG surgery

Following the analysis of predicted miRNA-targeted pathways, we investigated the complex correlations between the circulating miRNAome and the plasma, urinary and hepatic metabolomes. We found that a number of distinctive sets of miRNAs from observed global circulating miRNAs were strongly correlated with plasma lipids, TCA cycle intermediates, host-gut microbial co-metabolites, liver and plasma energy metabolites (Figure 2) and gut hormones (Supplementary Figure S4). Downregulated plasma miR-342-3p and upregulated miR-34c* in RYG-operated rats demonstrate a broad correlation with the liver, plasma and urinary metabolite profiles, indicating their extensive involvement in metabolic processes. Furthermore, mir-206, mir-1188, mir-1971 and mir-34c* are inversely correlated with plasma lipid fractions, whereas miR-320 and miR-342-3p and to a lesser extent miR-7*, exhibit a positive correlation. TCA cycle intermediates including citrate, succinate, 2-oxoglutarate and fumarate are positively correlated with miR-143, miR-126-3p, miR-146a, miR-150 and miR-155. Interestingly, these same miRNAs are inversely correlated with urinary host-microbial co-metabolites such as p-cresyl glucuronide, p-cresyl sulfate and phenylacetylglucose. In addition to miR-342-3p and miR-34c*, miR-872*, miR-463*, miR-30e, miR-2183, miR-1971, miR-150, miR-146a, miR-1188 and miR-93* all correlate with liver energy metabolism processes, such as glycolysis and glycogenesis involving glucose, glycogen and lactate.

Altered miR-122 expression levels in plasma and liver tissues are responsible for metabolic changes post RYG surgery

RYGB induced the strongest effects on miR-122, as downregulation of miR-122 was observed in both bariatric patients and our rodent model for RYGB, we subsequently focused on investigating miR-122-mediated metabolic pathways. We first confirmed miR-122 expression levels in both plasma and liver tissue using Taqman real-time quantitative PCR (Figure 3a). The Pearson correlation value of the results derived from Taqman low-density array cards and quantitative PCR is 0.9983 (P < 0.0001). Plasma miR-122 showed a 99% reduction in levels in RYGB-operated rats compared with SHAM controls, whereas hepatic miR-122 only showed 30% reduction of expression. We next examined a group of miR-122 targets, which are involved in key liver metabolic processes, such as the TCA cycle (Citrate synthase, glucose transport (Glut1, glucose transporter protein type 1), pentose phosphate pathway (G6pd, glucose-6-phosphate dehydrogenase), fatty-acid synthesis (Fasn, fatty-acid synthase), energy sensing (Pkpab1, adenosine monophosphate (AMP)-activated kinase beta 1), mitochondrial oxidation (Ucp2, uncoupling protein 2), gluconeogenesis (G6pc, glucose-6-phosphatase) and glycolysis (Aldoa, aldolase A). All mRNA targets are bona fide validated except for the putative targets UCP2 and AMPKβ1. These miR-122 targets in the liver all exhibited >1.5 fold increase in expression ranging from 1.53 to 1.91, except for Glut1 and G6pc. Although the alteration of Glut1 was not significant, it showed a clearly increased trend in the expression (P = 0.1061). G6pc expression, a validated miR-122 target, is surprisingly reduced >80% in the RYGB group (Figure 3c). G6pc expression was lowered rather than elevated in the hepatic tissue, suggesting perhaps regulatory mechanisms of G6pc other than miR-122 predominate. We then investigated whether miR-122 can directly modulate these mRNA targets by manipulating their expression in the hepatocyte-like B13H cell line (derived from a pancreatic AR42J-B13 cell line transdifferentiated with dexamethasone as primary hepatocytes and exenatide as primary hepatocytes are phenotypically unstable over the required time frame for the experiment). Transdifferentiation of this pancreatic cell to the B13H cell derivative, results phenotypically in a liver-like cell expressing liver-specific and enriched functional enzymes. In fact, miR-122, believed to be a hepatocyte-specific miRNA, was upregulated more than 400-fold during this trans-differentiation process (Supplementary Figure S5), consistent with the hepatic phenotype. In B13H cells transfected with miR-122 mimic, expression of Cs, Glut1, Fasn, Aldoa, G6pd, Pkpab1 and Ucp2 were all reduced (although the last three not significantly) in comparison with controls transfected with scrambled miRNA mimic (Figure 3d). Consistent with the aforementioned in vivo findings, the G6pc expression level was not affected by miR-122 in the B13H cell line. We concluded that miR-122 directly modulated Cs, Glut1, Fasn, Aldoa and to a lesser extent, G6pd, Ucp2 and Pkpab1.
We confirmed these transcriptional effects on protein expression in the liver tissues of RYGB- and SHAM-operated rats (Figure 3f). CS, catalyzing the formation of citrate from oxaloacetate and acetyl coenzyme A, is a mitochondrial marker and has a key role in regulating energy generation in TCA cycle and mitochondrial respiration. We found that RYGB rats exhibited a twofold increase in CS protein expression (Figure 3g). UCP2 protein level showed a 2.6-fold upregulation in the RYGB animals (Figure 3h), consistent with the altered mRNA expression level (1.7-fold upregulation). AMPK acts as an energy switch; in an...
energy-deficient status (high AMP:ATP; adenosine triphosphate ratio), AMPK can switch off ATP-consuming biosynthesis pathways, such as Fasn in adipocytes, cholesterol synthesis and gluconeogenesis in the liver, and switch on ATP-producing catabolic pathways, for example, fatty-acid oxidation and glycolysis in multiple tissues. AMPKβ1 units require activation via phosphorylation. Although the non-phosphorylated-AMPKβ1 was downregulated by 2.5 fold, the active phosphorylated-AMPKβ1 protein was significantly upregulated by twofold (Figures 3i and j).

DISCUSSION
Bariatric surgery has been shown to markedly alter circulating miRNAs in patients, in particular, downregulation of miR-122 by 94.7%. However, the metabolic functions and consequences of these deregulated miRNAs have not been clarified or validated to date. We therefore investigated the correlation of the miRNome and metabolites in a bariatric surgical model to elucidate energetic, microbial and neuronal signaling mechanisms of disease resolution. The mechanisms of RYGB surgery are complex; from our study and the work of others, it is apparent that circulating miRNAs could potentially work as a class of hormone, so-called miRormone, to mediate energy metabolism resulting in weight loss and potentially reset the brain-food rewarding system. Decreased plasma levels of miR-342-3p, miR-320, miR-139-5p and miR-146a observed in our study suggest RYGB surgery impact on multiple neurodegenerative disease-related pathways. Patients with Parkinson’s disease commonly experience unintended weight loss factors including reduced food intake owing to dysphagia, increased resting energy expenditure and potential peptide hormones, such as ghrelin, could account for the underlying mechanisms. There is increased evidence suggesting a beneficial effect of bariatric operations on neurodegenerative disease based on surgical activity on caloric restriction, glycaemic control and gut hormonal modulation. The common miRNA-targeted pathways between bariatric surgery and Parkinson’s disease suggest that surgery-induced weight loss may share certain mechanistic pathways with unintended weight loss in Parkinson’s disease patients.

MiR-122 is a liver-produced miRNA and its less marked reduced expression in the liver compared with plasma suggests a restrained miR-122 release into the blood stream after RYGB surgery. By antagonizing miR-122 with LNA (locked-nucleic-acid-modified oligonucleotide)-anti-miR-122 in diet-induced obese mice for 6 weeks, a 30% decrease in total cholesterol levels was achieved without lipid accumulation in the liver and tested miR-122 mRNA targets were similar to our findings except for G6pc, which was upregulated. Esau et al. demonstrated that injecting miR-122 antisense oligonucleotide into mice for 5 weeks results in reduced plasma cholesterol levels, increased hepatic fatty-acid oxidation, decreased hepatic fatty-acid and cholesterol synthesis rates; effects that are also seen in primates. Following RYGB surgery, we observed increased glucose transportation, accelerated glycolysis and inhibited gluconeogenesis in the RYGB rat model. Glut1, a glucose transporter, was upregulated consistent with the decreased miR-122 expression in the liver and increased levels of hepatic glucose and glycogen were observed, indicating that RYGB promotes glucose transportation and glycogen synthesis. Our metabolic and miR-122 target expression data show that RYGB surgery suppresses gluconeogenesis and stimulates glycolysis, as evidenced by the
downregulation of G6pc and upregulation of Aldoa, together with elevated concentrations of glycolysis end products including pyruvate, alanine and lactate in the liver and plasma (Figure 4). Mencarelli et al. 24 have recently investigated the effects of ileal interposition, where the distal ileum is relocated into the proximal jejunum, which mimics a partial procedure of RYGB surgery. Consistent with our results, the hepatic expression of G6pc was also suppressed in this ileal interposition model. Furthermore, G6pd was found to be upregulated and this is an indicator for oxidative activity of the pentose phosphate pathway. It is likely that G6pd is stimulated by the unbalanced ratio of NADPH/NADP+ (normally 100:1 in the hepatic cytosol) to favor NADPH production. This unbalanced ratio could be because of the utilization of NADPH in the liver by reductive biosynthesis, such as lipid biosynthesis. G6PD expression and enzyme activity have been reported to be upregulated in the Roux limb of RYGB-operated rats, as well as Glut1, 25 and the authors concluded that the reprogramming of intestinal glucose, including enhanced basolateral glucose uptake, augmented glycolysis and stimulated pentose phosphate pathway, could contribute to the glycemic control after RYGB. Decreased miR-122 levels induced the upregulation of Cs (CS) and Ucp2 (UCP2). CS is a well-studied rate-limiting enzyme in the TCA cycle. Although the metabolic function of UCP2 is still controversial and varies between various types of tissues, it is believed to have a pivotal role in obesity, diabetes, metabolic

**Figure 3.** Expression levels of miR-122 and its targets in vitro and in vivo. The Roux-en-Y gastric bypass results in the altered miR-122 expression levels in plasma (a) and the liver (b) measured by quantitative PCR. (c) The expression levels of miR-122 mRNA targets, including citrate synthase (Cs), glucose transporter protein type 1 (Glut1), glucose-6-phosphate dehydrogenase (G6pd), fatty-acid synthase (Fasn), AMPK-activated kinase beta 1 (Prkab1), uncoupling protein 2 (Ucp2), glucose-6-phosphatase (G6pc) and aldolase A (Aldoa), are measured by quantitative PCR in the liver of RYGB- (n = 8) and SHAM- (n = 5) operated animals. (d) These targets were evaluated in B13H cells transfected with miR-122 mimic (treatment, n = 4) or scrambled miRNA (control, n = 4) and measured by quantitative PCR. (e) A previous in vivo study by Elamn et al (Data were extracted from Array Express Experiment No. E-MEXP-1406, n = 5 each group). (f) Immunoblot of the hepatic protein expression levels of citrate synthase, UCP2, AMPK-beta 1 and phosphorylated AMPK-beta 1 in the RYGB- and sham-operated animals. (g–j) show quantified protein expressions of citrate synthase, UCP2, AMPK-beta 1 and phospho-AMPK-beta 1, respectively. All data represent mean ± s.e.m. (RYGB, n = 8; SHAM, n = 5), unless otherwise specified in each figure. *P < 0.05; **P < 0.01; ***P < 0.001.
syndrome and several neurodegenerative diseases. Hepatic UCP2, which uncouples oxidative phosphorylation with ATP production, is highly associated with oxidative phosphorylation and fatty-acid oxidation. UCP2 is responsible for proton translocation from the intermembrane space to the mitochondria matrix and uncouples proton flux with ATP synthesis. The upregulation of UCP2 and CS in the liver indicates that the RYGB-operated animals exhibit higher cellular metabolic activity such as favored fatty-acid oxidation and increased TCA cycle metabolism, which is further supported by the decreased levels of urinary TCA cycle intermediates detected by metabonomic analysis. Furthermore, UCP2 is a downstream effector of the energy sensor AMPK coded by the Prkab1 gene. In the present study, we also observed increased Prkab1 expression followed by upregulated UCP2. After RYGB, fat stored in adipose tissue is thought to be mobilized and metabolized in the liver, generating increased levels of free fatty acids, which could result in upregulated UCP2. It has been shown that increased UCP2 could not only promote the energy expenditure toward lipid utilization and compensate reduction of reactive oxygen species, but also reduce oxidative stress and protect mitochondria during fatty-acid β-oxidation. This is consistent with decreased reactive oxygen species reported in patients after bariatric surgery. Hence, UCP2 and oxidative decoupling may contribute to postoperative weight loss. We observed that fatty-acid synthase (Fasn) also increased following RYGB surgery. The underlying reason for the increase in Fasn is unclear, but one possibility is that RYGB extensively affects lipid metabolism and leads to a restoration of adipose redox balance. Therefore, further studies should address lipid metabolism during the re-adjustment period after bariatric surgery.

In conclusion, we have demonstrated that RYGB surgery significantly modified metabolite and miRNA profiles of SD rats, resulting in substantial weight loss. We have demonstrated that miR-122 contributed to the control of energy metabolism with increased glucose transportation, glycolysis, TCA cycle, pentose phosphate shunt and decreased gluconeogenesis and ketone body generation (Figure 4), suggesting an overall increased energy expenditure status. By correlating the circulating miRNAome and metabolome data, we were able to generate for the first time a comprehensive landscape of the crosstalk between miRNAs and metabolic pathways that point to a systemic regulation of processes including multiple axes of energy metabolism and suggested impact on the gut-brain axis. Follow-up studies will allow a detailed understanding of miRNAs responsible for regulating specific metabolic pathways, and conversely identifying metabolites capable of regulating the expression and activity of specific miRNAs. Our study highlights the value of transomic modeling and opens up a new window to further understand fundamental mechanisms associated with metabolic surgery and potential therapeutic targets for obesity and diabetes treatment.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
Jia V Li and the metabonomics study were supported by Imperial College Junior Research Fellowship. Qianxin Wu was supported by Imperial College International Student Scholarship and Kwock Foundation-Imperial College PhD Scholarship. Carel W le Roux supported by Science Foundation Ireland (12/Y1/B2480).
1134 References

1 Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. *Nat Med* 2006; 12: 62–66.

2 Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al. Bariatric surgery: a systematic review and meta-analysis. *JAMA* 2004; 292: 1724–1737.

3 Stylopoulos N, Hoppin AG, Kaplan LM. Roux-en-Y Gastric Bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. *Obesity* 2009; 17: 1839–1847.

4 Atrashian H, Bueter M, Ahmed K, Suliman A, Bloom SR, Darzi A et al. Metabolic surgery: an evolution through bariatric animal models. *Obes Rev* 2010; 11: 907–920.

5 Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y et al. Human gut microbiota in obesity and after gastric bypass. *PNAS* 2009; 106: 2365–2370.

6 Li JV, Ashra ...-Y gastric bypass in mice. *J Proteome Res* 2013; 12: 477–487.

7 Ortega FJ, Mercader JM, Catalan V, Moreno-Navarrete JM, Pueyo N, Sabater M et al. Targeting the circulating microRNA signature of obesity. *Clin Chem* 2013; 59: 781–792.

8 Wallace K, Fairhall EA, Charlton KA, Wright MC. AR42J-8-13 cell: an expandable progenitor to generate an unlimited supply of functional hepatocytes. *Toxicology* 2010; 278: 277–287.

9 Hardie DG. AMPK: a key regulator of energy balance in the single cell and the whole organism. *Int J Obes* 2008; 32: 57–512.

10 Mitchellhill KI, Michell BJ, House CM, Stapleton D, Dyck J, Gamble J et al. Posttranslational modifications of the SAMP-activated protein kinase beta1 subunit. *J Biol Chem* 1997; 272: 24475–24479.

11 Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestzen G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. *Nat Rev Clin Oncol* 2011; 8: 467–477.

12 Chen H, Zhang SM, Hernán MA, Willett WC, Ascherio A. Weight loss in Parkinson’s disease. *Ann Neurol* 2003; 53: 676–679.

13 Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. *Lancet Neurol* 2003; 2: 107–116.

14 Ashrafian H, Harling L, Darzi A, Athanasiou T. Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions? *Metab Brain Dis* 2013; 28: 341–353.

15 Elmen J, Lindow M, Shultz S, Lawrence M, Petri A, Obad S et al. LNA-mediated microRNA silencing in non-human primates. *Nature* 2008; 452: 896–910.

16 Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. *Cell Metab* 2006; 3: 87–98.

17 Elmén J, Lindow M, Silhataroglu A, Bak M, Christensen M, Lind-Thomsen A et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. *Nucleic Acids Res* 2008; 36: 1153–1162.

18 Mencarelli A, Renga B, D’Amore C, Santorelli C, Graziosi L, Bruno A et al. Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. *Diabetes* 2013; 62: 3384–3393.

19 Crockford DJ, Holmes E, Lindon JC, Plumb RS, Zirah S, Bruce SJ. The mix of hormones and biomarkers. *Clin Chem* 2006; 52: 790.

20 Zhang Y-G, Baffy G, Perret P, Krauss S, Peroni O, Grujic D et al. Uncoiling protein-2 negatively regulates insulin secretion and is a major link between obesity, β cell dysfunction, and type 2 diabetes. *Cell* 2001; 105: 745–755.

21 Bechmann I, Diano S, Warden CH, Barfai T, Nitsch R, Horvath TL. Brain mitochondrial uncoupling protein 2 (UCP2): a protective stress signal in neuronal injury. *Biochem Pharmacol* 2002; 64: 363–367.

22 Johansson L, Roos M, Kullberg J, Weis J, Ahlstrom H, Sundborn M et al. Lipid mobilization following Roux-en-Y gastric bypass examined by magnetic resonance imaging and spectroscopy. *Obes Surg* 2008; 18: 1297–1304.

23 Mattiasson G, Sullivan PG. The emerging functions of UCP2 in health, disease, and therapeutics. *Antioxid Redox Signal* 2006; 8: 1–38.

24 Castro MC, Massa ML, Del Zotto H, Gagliardino JJ, Francini F. Rat liver uncoupling protein 2: changes induced by a fructose-rich diet. *Life Sci* 2001; 69: 609–614.

25 Collins P, Jones C, Choudhury S, Damelin L, Hodgson J. Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. *Biochem Pharmacol* 2005; 67: 880–887.

26 Patterson AD, Shah YM, Matsubara T, Krausz KW, Gonzalez FJ. Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity. *Hepatology* 2012; 56: 281–290.

27 Ueda Y, Hajri T, Peng D, Marks-Shulman PA, Tamboli RA, Shukrallah B et al. Reduction of 8-iso-prostaglandin F2α in the first week after Roux-en-Y gastric bypass surgery. *Obesity* 2011; 19: 1663–1668.

28 Huang H, Kasumov T, Gazmaitis P, Heneghan HM, Kashyap SR, Schauer PR et al. Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients. *Obesity* 2011; 19: 2325–2340.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/